Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 2.72
1.12 %
$ 4.06 M
Market Cap
-2.21
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Evoke Pharma, Inc.
| Current Assets | 17.2 M |
| Cash & Short-Term Investments | 13.6 M |
| Receivables | 2.42 M |
| Other Current Assets | 1.22 M |
| Non-Current Assets | 281 K |
| Long-Term Investments | 0 |
| PP&E | 154 K |
| Other Non-Current Assets | 127 K |
| Current Liabilities | 10.4 M |
| Accounts Payable | 2.34 M |
| Short-Term Debt | 5.06 M |
| Other Current Liabilities | 2.98 M |
| Non-Current Liabilities | 101 K |
| Long-Term Debt | 101 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Evoke Pharma, Inc.
| Revenue | 10.2 M |
| Cost Of Revenue | 357 K |
| Gross Profit | 9.89 M |
| Operating Expenses | 15.1 M |
| Operating Income | -5.2 M |
| Other Expenses | 148 K |
| Net Income | -5.35 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Evoke Pharma, Inc.
| Net Income | -5.35 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 773 K |
| Change in Working Capital | -1.4 M |
| Others | 518 K |
| Free Cash Flow | -5.46 M |
Wall Street Analysts Price Targets
Evoke Pharma, Inc.
Wall Street analysts predict an average 1-year price target for EVOK of $18 , with forecasts ranging from
a
low of
$18 to a high of $18 .
EVOK Lowest Price Target
Wall Street Target
18 USD
561.76%
EVOK Average Price Target
Wall Street Target
18 USD
561.76%
EVOK Highest Price Target
Wall Street Target
18 USD
561.76%
4. DIVIDEND
ANALYSIS
EVOK does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Evoke Pharma, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
180 USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
globenewswire.com
- 1 month ago
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA.
globenewswire.com
- 2 months ago
evoke makes a steady exit from the Q1 starting gate
Evoke PLC (LSE:EVOK) has kicked off 2025 with a steady start, reporting first-quarter revenue of £437.00 million—up 1% on last year and pretty much bang on with what it had guided. So far this year, revenue is up around 4%, and the company says it's still aiming for full-year growth in the 5-9% range.
proactiveinvestors.co.uk
- 2 months ago
William Hill owner Evoke falls at the first-quarter update
Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year.
proactiveinvestors.co.uk
- 3 months ago
Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Daniel Kontoh-Boateng – DKB Partners Matt D'Onofrio – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, GIMOTI, EVERSANA Mark Kowieski – Chief Financial Officer Conference Call Participants Yale Jen – Laidlaw & Company Operator Good afternoon, and welcome to the Evoke Pharma Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently all callers have been placed in a listen-only mode and following management's prepared remarks, the call will be opened for your questions.
seekingalpha.com
- 3 months ago
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif.
globenewswire.com
- 3 months ago
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025
SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes.
globenewswire.com
- 4 months ago
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors
SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke's commercial strategy and growth potential.
globenewswire.com
- 4 months ago
William Hill owner Evoke expects earnings to beat market forecasts
Expect shares in William Hill owner Evoke PLC to get off to a strong start when the market opens. That's because the bookmaker said full-year earnings for 2024 will surpass market expectations, with strong double-digit revenue growth in the fourth quarter driven by its online business.
proactiveinvestors.co.uk
- 5 months ago
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA's recent update regarding domperidone supply.
globenewswire.com
- 6 months ago
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company's robust intellectual property estate for its innovative GIMOTI® (metoclopramide) nasal spray.
globenewswire.com
- 7 months ago
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year
globenewswire.com
- 7 months ago
8. Profile
Summary
Evoke Pharma, Inc. EVOK
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 4.06 M
Dividend Yield
0.00%
Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Contact
420 Stevens Avenue, Solana Beach, CA, 92075
https://www.evokepharma.com
IPO
Date
Sept. 25, 2013
Employees
3
Officers
Mr. Christopher Quesenberry
Chief Commercial Officer - Gimoti (TM)
Mr. Mark A. Kowieski CPA
Chief Financial Officer, Treasurer & Secretary
Mr. Matthew J. D'Onofrio MBA
Co-Founder, Chief Executive Officer & Director
Dr. Marilyn R. Carlson D.M.D., M.D., RAC.
Chief Medical Officer